Oxycodone And Acetaminophen
NDC Package 67296-1815-2
Package Information
Oxycodone And Acetaminophen is tablets is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.Limitations of UseBecause of the risks of addiction, abuse, and misuse, with opioids, even at recommended doses [see WARNINGS], reserve Oxycodone and Acetaminophen Tablets for use in patients for whom alternative treatment options [e.g., non-opioid analgesics]• Have not been tolerated, or are not expected to be tolerated,• Have not provided adequate analgesia, or are not expected to provide adequate analgesia . Marketed by Redpharm Drug,inc., this product is identified by NDC 67296-1815 and is authorized under FDA application ANDA207419.
Identification & Billing
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 67296 - Redpharm Drug,inc.
- 67296-1815 - Oxycodone And Acetaminophen
- 67296-1815-2 - 20 TABLET in 1 BOTTLE
- 67296-1815 - Oxycodone And Acetaminophen
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (67296-1815). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 67296-1815-2 identifies a specific commercial package of 20 tablet in 1 bottle of Oxycodone And Acetaminophen, labeled by Redpharm Drug,inc.. This is formulated for use and contains as the active substance.
Is this product currently listed with the FDA?
This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Redpharm Drug,inc. on April 11, 2017. The current certification is valid through December 31, 2025.
How is this Redpharm Drug,inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 67296181502. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.
